X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TEVA PHARMA
Dec-13
DISHMAN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3742,658-   
Low Rs1292,309-   
Sales per share (Unadj.) Rs197.81,525.2-  
Earnings per share (Unadj.) Rs21.295.3-  
Cash flow per share (Unadj.) Rs34.7218.6-  
Dividends per share (Unadj.) Rs2.0083.41-  
Dividend yield (eoy) %0.83.4 23.7%  
Book value per share (Unadj.) Rs179.91,694.2-  
Shares outstanding (eoy) m80.69848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.1%   
Avg P/E ratio x11.926.1 45.5%  
P/CF ratio (eoy) x7.211.4 63.8%  
Price / Book Value ratio x1.41.5 95.4%  
Dividend payout %9.487.5 10.8%   
Avg Mkt Cap Rs m20,3062,105,694 1.0%   
No. of employees `0000.844.9 1.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.728,777.2 66.9%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.11,797.7 114.8%   
INCOME DATA
Net Sales Rs m15,9611,293,392 1.2%  
Other income Rs m2650-   
Total revenues Rs m16,2261,293,392 1.3%   
Gross profit Rs m4,103354,196 1.2%  
Depreciation Rs m1,091104,546 1.0%   
Interest Rs m94425,404 3.7%   
Profit before tax Rs m2,334224,246 1.0%   
Minority Interest Rs m01,019 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-147,205 0.0%   
Tax Rs m624-2,738 -22.8%   
Profit after tax Rs m1,71180,797 2.1%  
Gross profit margin %25.727.4 93.9%  
Effective tax rate %26.7-1.2 -2,188.8%   
Net profit margin %10.76.2 171.6%  
BALANCE SHEET DATA
Current assets Rs m11,018873,552 1.3%   
Current liabilities Rs m9,517761,812 1.2%   
Net working cap to sales %9.48.6 108.8%  
Current ratio x1.21.1 101.0%  
Inventory Days Days11091 121.7%  
Debtors Days Days3596 36.3%  
Net fixed assets Rs m16,304422,450 3.9%   
Share capital Rs m1613,184 5.1%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,436,714 1.0%   
Long term debt Rs m4,189661,340 0.6%   
Total assets Rs m29,8052,955,816 1.0%  
Interest coverage x3.59.8 35.3%   
Debt to equity ratio x0.30.5 62.7%  
Sales to assets ratio x0.50.4 122.4%   
Return on assets %8.93.6 248.0%  
Return on equity %11.85.6 209.6%  
Return on capital %17.54.9 355.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786206,100 1.4%  
From Investments Rs m-1,529-73,029 2.1%  
From Financial Activity Rs m-941-247,231 0.4%  
Net Cashflow Rs m316-114,160 -0.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare DISHMAN PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare DISHMAN PHARMA With: SANOFI INDIA  FRESENIUS KABI ONCO.  ALKEM LABORATORIES  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SHASUN PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS